THALES
18.9.2023 14:01:30 CEST | Business Wire | Press release
Thales, the leading global technology and security provider, today announced the launch of CipherTrust Cloud Key Management's Hold Your Own Key (HYOK) in Oracle Cloud Infrastructure (OCI) across all 45 Oracle Cloud Regions—including the recently launched Oracle EU Sovereign Cloud—and OCI’s other distributed cloud offerings. To help meet continued customer demand and the accelerated growth of the OCI platform, HYOK will help OCI customers achieve their data sovereignty and other compliance objectives more easily by encrypting data in OCI with keys that are controlled and managed outside of the cloud platform. The new HYOK capabilities expand on existing support for Bring Your Own Key (BYOK) in OCI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918263668/en/
©Thales
According to the 2023 Thales Cloud Security Study, while the world has become cloud-first, operational complexity in cloud environments remains a significant obstacle for organizations. Overall, cloud security awareness has improved, but concerns around securing data are also rising, with over half (55 percent) of security professionals indicating it’s more complex to manage data in the cloud than it is in on-premises environments. As a result, as cloud usage grows, organizations need a new way to effectively secure cloud environments.
The CipherTrust Cloud Key Management integration enables OCI customers to store and manage their encryption keys outside OCI in a virtual or physical appliance that is entirely under their control and outside of the cloud. Customers can also localize their encryption keys wherever they choose and maintain control of their encrypted data in cloud environments. This approach helps address some of the key privacy and data sovereignty requirements organizations face while making it easier to demonstrate compliance to regulators.
The availability of the Thales external key management solution can help accelerate the move of sensitive data into Oracle Cloud Regions by storing the key in a location that is different than the encrypted data. This enables customers to maintain the same process for managing and controlling encryption keys, whether those keys are used on-premises or in the cloud
Thales CipherTrust Cloud Key Management, the industry-leading multi-cloud encryption key lifecycle management solution, alleviates operational barriers across clouds and hybrid environments. The HYOK functionality gives OCI customers the external key management capabilities necessary to navigate today’s cloud-driven landscape and remain in charge of their data, not just in OCI, but across other cloud providers.
Todd Moore, Vice President of Data Security Products at Thales: “Businesses are increasingly shifting away from legacy on-premises deployments and need assistance in moving their data to the cloud while maintaining security and compliance. As the industry leader in external key management, we’re proud to be the first to support HYOK features in OCI, equipping OCI customers with the necessary solutions to be successful in this journey. To further this best-in-class experience for our combined customer base, Thales is also the first supporting vendor for Oracle EU Sovereign Cloud initiatives.”
Jeppe Larsen, Senior Vice President, OCI Security and Identity at Oracle: “We’re dedicated to making OCI the most trusted cloud for security-sensitive workloads, including those in highly regulated regions and industries. Oracle EU Sovereign Cloud helps customers operating in Europe to address their data sovereignty requirements, and the HYOK integration with Thales enhances that offering. In addition, this partnership and integration will benefit U.S. customers in regulated industries such as financial services by enabling them to take full advantage of OCI, with the privacy and security benefits of HYOK from Thales.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion. |
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918263668/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom